{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:13:11Z","timestamp":1787663591001,"version":"build-2736575974"},"reference-count":52,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mutations in the gene encoding for complement regulator factor H (FH) severely disrupt its normal function to protect human cells from unwanted complement activation, resulting in diseases such as atypical hemolytic uremic syndrome (aHUS). aHUS presents with severe hemolytic anemia, thrombocytopenia, and renal disease, leading to end-stage renal failure. Treatment of severe complement-mediated disease, such as aHUS, by inhibiting the terminal complement pathway, has proven to be successful but at the same time fails to preserve the protective role of complement against pathogens. To improve complement regulation on human cells without interfering with antimicrobial activity, we identified an anti-FH monoclonal antibody (mAb) that induced increased FH-mediated protection of primary human endothelial cells from complement, while preserving the complement-mediated killing of bacteria. Moreover, this FH-activating mAb restored complement regulation in sera from aHUS patients carrying various heterozygous mutations in FH known to impair FH function and dysregulate complement activation. Our data suggest that FH normally circulates in a less active conformation and can become more active, allowing enhanced complement regulation on human cells. Antibody-mediated potentiation of FH may serve as a highly effective approach to inhibit unwanted complement activation on human cells in a wide range of hematological diseases while preserving the protective role of complement against pathogens.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018025692","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T22:05:51Z","timestamp":1551132351000},"page":"621-632","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3469-8454","authenticated-orcid":false,"given":"Richard B.","family":"Pouw","sequence":"first","affiliation":[{"name":"Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"},{"name":"Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children\u2019s Hospital, Amsterdam UMC, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke C.","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"de Gast","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-336X","authenticated-orcid":false,"given":"Anna E.","family":"van Beek","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"},{"name":"Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children\u2019s Hospital, Amsterdam UMC, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P.","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Laboratory of Pediatric Nephrology, Department of Development and Regeneration, Katholieke Universiteit Leuven, Leuven, Belgium;"},{"name":"Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Q.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"van der Ende","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Netherlands Reference Laboratory for Bacterial Meningitis, Center for Infection and Immunity Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4212-1233","authenticated-orcid":false,"given":"Pilar","family":"S\u00e1nchez-Corral","sequence":"additional","affiliation":[{"name":"Complement Research Group, Hospital La Paz Institute for Health Research, La Paz University Hospital, and Centre for Biomedical Network Research on Rare Diseases, Madrid, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-3370","authenticated-orcid":false,"given":"Taco W.","family":"Kuijpers","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children\u2019s Hospital, Amsterdam UMC, Amsterdam, The Netherlands;"},{"name":"Department of Blood Cell Research, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Wouters","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"issue":"7","key":"2020021108341524600_B1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"2020021108341524600_B2","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.4049\/jimmunol.149.8.2592","article-title":"Ultrastructures and interactions of complement factors H and I","volume":"149","author":"DiScipio","year":"1992","journal-title":"J Immunol"},{"issue":"5","key":"2020021108341524600_B3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1006\/jmbi.2001.4720","article-title":"Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling","volume":"309","author":"Aslam","year":"2001","journal-title":"J Mol Biol"},{"issue":"1","key":"2020021108341524600_B4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jmb.2009.06.010","article-title":"Electrostatic interactions contribute to the folded-back conformation of wild type human factor H","volume":"391","author":"Okemefuna","year":"2009","journal-title":"J Mol Biol"},{"issue":"1","key":"2020021108341524600_B5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jmb.2007.09.026","article-title":"The regulatory SCR-1\/5 and cell surface-binding SCR-16\/20 fragments of factor H reveal partially folded-back solution structures and different self-associative properties","volume":"375","author":"Okemefuna","year":"2008","journal-title":"J Mol Biol"},{"issue":"5","key":"2020021108341524600_B6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jmb.2012.09.013","article-title":"Solution structure of CCP modules 10-12 illuminates functional architecture of the complement regulator, factor H","volume":"424","author":"Makou","year":"2012","journal-title":"J Mol Biol"},{"issue":"23","key":"2020021108341524600_B7","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1021\/bi4003452","article-title":"Functional anatomy of complement factor H","volume":"52","author":"Makou","year":"2013","journal-title":"Biochemistry"},{"issue":"10","key":"2020021108341524600_B8","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/eji.1830261017","article-title":"Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H","volume":"26","author":"K\u00fchn","year":"1996","journal-title":"Eur J Immunol"},{"issue":"20","key":"2020021108341524600_B9","doi-asserted-by":"crossref","first-page":"10996","DOI":"10.1073\/pnas.93.20.10996","article-title":"Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis","volume":"93","author":"Sharma","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"36","key":"2020021108341524600_B10","doi-asserted-by":"crossref","first-page":"27657","DOI":"10.1074\/jbc.M002903200","article-title":"Each of the three binding sites on complement factor H interacts with a distinct site on C3b","volume":"275","author":"Jokiranta","year":"2000","journal-title":"J Biol Chem"},{"issue":"12","key":"2020021108341524600_B11","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.4049\/jimmunol.157.12.5422","article-title":"Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H","volume":"157","author":"Blackmore","year":"1996","journal-title":"J Immunol"},{"issue":"7","key":"2020021108341524600_B12","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.4049\/jimmunol.160.7.3342","article-title":"Identification of the second heparin-binding domain in human complement factor H","volume":"160","author":"Blackmore","year":"1998","journal-title":"J Immunol"},{"issue":"4","key":"2020021108341524600_B13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0002-9440(10)61205-9","article-title":"Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site","volume":"167","author":"Jokiranta","year":"2005","journal-title":"Am J Pathol"},{"issue":"10","key":"2020021108341524600_B14","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1016\/j.molimm.2006.12.001","article-title":"The C-terminus of complement factor H is essential for host cell protection","volume":"44","author":"J\u00f3zsi","year":"2007","journal-title":"Mol Immunol"},{"issue":"4","key":"2020021108341524600_B15","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.181.4.2610","article-title":"A new map of glycosaminoglycan and C3b binding sites on factor H","volume":"181","author":"Schmidt","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"2020021108341524600_B16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"issue":"2","key":"2020021108341524600_B17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1681\/ASN.V122297","article-title":"The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20","volume":"12","author":"Caprioli","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2020021108341524600_B18","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/344515","article-title":"Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome","volume":"71","author":"S\u00e1nchez-Corral","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"24","key":"2020021108341524600_B19","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","article-title":"Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease","volume":"12","author":"Caprioli","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2020021108341524600_B20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2020021108341524600_B21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.imbio.2012.07.021","article-title":"Complement dysregulation and disease: from genes and proteins to diagnostics and drugs","volume":"217","author":"de Cordoba","year":"2012","journal-title":"Immunobiology"},{"issue":"3","key":"2020021108341524600_B22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2020021108341524600_B23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2011.152","article-title":"Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome","volume":"80","author":"Strobel","year":"2011","journal-title":"Kidney Int"},{"issue":"11","key":"2020021108341524600_B24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"2020021108341524600_B25","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.imbio.2013.04.021","article-title":"Primary complement C5 deficiencies - molecular characterization and clinical review of two families","volume":"218","author":"Schejbel","year":"2013","journal-title":"Immunobiology"},{"key":"2020021108341524600_B26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.imbio.2015.06.012","article-title":"Therapeutic control of complement activation at the level of the central component C3","volume":"221","author":"Ricklin","year":"2016","journal-title":"Immunobiology"},{"issue":"12","key":"2020021108341524600_B27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2020021108341524600_B28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molimm.2018.06.008","article-title":"Developments in anti-complement therapy; from disease to clinical trial","volume":"102","author":"Harris","year":"2018","journal-title":"Mol Immunol"},{"issue":"2","key":"2020021108341524600_B29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.kint.2017.07.015","article-title":"Complete functional characterization of disease-associated genetic variants in the complement factor H gene","volume":"93","author":"Merinero","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"2020021108341524600_B30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1681\/ASN.2017050518","article-title":"Factor H competitor generated by gene conversion events associates with atypical hemolytic uremic syndrome","volume":"29","author":"Goicoechea de Jorge","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2020021108341524600_B31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ki.2011.291","article-title":"Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance","volume":"81","author":"Tortajada","year":"2012","journal-title":"Kidney Int"},{"issue":"1","key":"2020021108341524600_B32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1681\/ASN.2005080868","article-title":"Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions","volume":"17","author":"J\u00f3zsi","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2020021108341524600_B33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molimm.2004.01.003","article-title":"Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H","volume":"41","author":"S\u00e1nchez-Corral","year":"2004","journal-title":"Mol Immunol"},{"issue":"2","key":"2020021108341524600_B34","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1053\/j.ajkd.2005.11.007","article-title":"Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment","volume":"47","author":"Davin","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2020021108341524600_B35","doi-asserted-by":"crossref","first-page":"e0152164","DOI":"10.1371\/journal.pone.0152164","article-title":"Complement factor H-related protein 3 serum levels are low compared to factor H and mainly determined by gene copy number variation in CFHR3","volume":"11","author":"Pouw","year":"2016","journal-title":"PLoS One"},{"issue":"13","key":"2020021108341524600_B36","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1074\/jbc.M110.211839","article-title":"Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities","volume":"286","author":"Pechtl","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"2020021108341524600_B37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0022-1759(93)90240-8","article-title":"Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway","volume":"163","author":"Wolbink","year":"1993","journal-title":"J Immunol Methods"},{"issue":"4","key":"2020021108341524600_B38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.molimm.2009.10.017","article-title":"Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease","volume":"47","author":"Kuijpers","year":"2010","journal-title":"Mol Immunol"},{"issue":"4","key":"2020021108341524600_B39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.imbio.2015.12.009","article-title":"Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients","volume":"221","author":"Schmidt","year":"2016","journal-title":"Immunobiology"},{"issue":"11","key":"2020021108341524600_B40","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J Immunol"},{"issue":"6","key":"2020021108341524600_B41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.it.2015.04.008","article-title":"Factor H-related proteins determine complement-activating surfaces","volume":"36","author":"J\u00f3zsi","year":"2015","journal-title":"Trends Immunol"},{"issue":"2","key":"2020021108341524600_B42","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4049\/jimmunol.1501919","article-title":"Comparative analysis of novel complement-targeted inhibitors, miniFH, and the natural regulators factor H and factor H-like protein 1 reveal functional determinants of complement regulation","volume":"196","author":"Harder","year":"2016","journal-title":"J Immunol"},{"key":"2020021108341524600_B43","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1501388","article-title":"Complement evasion mediated by enhancement of captured factor H: implications for protection of self-surfaces from complement","volume-title":"J Immunol","author":"Herbert","year":"2015"},{"issue":"2","key":"2020021108341524600_B44","doi-asserted-by":"crossref","first-page":"e32187","DOI":"10.1371\/journal.pone.0032187","article-title":"Structural analysis of the C-terminal region (modules 18-20) of complement regulator factor H (FH)","volume":"7","author":"Morgan","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"2020021108341524600_B45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.it.2012.09.004","article-title":"The inflammatory response in sepsis","volume":"34","author":"Bosmann","year":"2013","journal-title":"Trends Immunol"},{"issue":"2","key":"2020021108341524600_B46","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4049\/jimmunol.1300269","article-title":"An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H","volume":"191","author":"Hebecker","year":"2013","journal-title":"J Immunol"},{"issue":"6","key":"2020021108341524600_B47","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/ki.2015.233","article-title":"An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy","volume":"88","author":"Nichols","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"2020021108341524600_B48","first-page":"1141","article-title":"The MFHR1 fusion protein is a novel synthetic multitarget complement inhibitor with therapeutic potential","volume":"29","author":"Michelfelder","year":"2018"},{"issue":"17","key":"2020021108341524600_B49","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2020021108341524600_B50","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1182\/blood-2011-12-398792","article-title":"The complement receptor 2\/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment","volume":"119","author":"Risitano","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2020021108341524600_B51","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.imbio.2012.07.024","article-title":"The complement system in ischemia-reperfusion injuries","volume":"217","author":"Gorsuch","year":"2012","journal-title":"Immunobiology"},{"key":"2020021108341524600_B52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molimm.2017.05.014","article-title":"Complement in renal transplantation: The road to translation","volume":"89","author":"Jager","year":"2017","journal-title":"Mol Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/621\/1631147\/advances025692.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/621\/1631147\/advances025692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T22:54:53Z","timestamp":1694645693000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/4\/621\/246756\/Potentiation-of-complement-regulator-factor-H"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,25]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018025692","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,25]]}}}